Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition

NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company’s proprietary PD‑L1/4‑1BB bispecific antibody, has been granted Orphan Drug Designation (ODD) by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC). This is the third Orphan Drug Designation for opamtistomig, following designations in the U.S. Food and Drug Administration (FDA) and the European Commission (EC), marking a further expansion of its global regulatory recognition into a strategically important Asian market.